Organon, Daiichi Sankyo Europe enter commercialization pact for Nilemdo

Organon (OGN) announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo is a drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins. Under the terms of the agreement, Organon will distribute and promote Nilemdo in France, Denmark, Iceland, Sweden, Finland and Norway. Daiichi Sankyo Europe will remain the marketing authorization holder for the product and Organon will be local representative in the territory.